GSK's Augmentin Leads Indian Pharma Market in October with Rs 843 Crore Sales: Pharmatrac Report

Besides Augmentin, USV’s Glycomet GP also continue to lead the pack, while newer entrants like Alkem’s Pan and Abbott’s Ryzodeg have made significant strides in a rapidly changing market.

According to a recent Pharmatrac report, the rankings of the top-selling pharmaceutical brands in India have evolved, reflecting the industry's ability to adapt to the changing healthcare needs of the population. A closer analysis of both the Moving Annual Total (MAT) and Month-to-Highlight (MTH) performances for October 2024 reveals interesting trends and significant movements in the rankings of leading brands.

Top Brands by Sales Value (MAT Oct’24)

GSK’s Augmentin

GSK’s Augmentin continues to reign as the top-selling drug in India, with a sales value of Rs 843 crore for the month. Despite a slight -0.8% decline in unit growth, the brand managed to post a 1.8% increase in value for October, reinforcing its dominant position in the antibiotic market. The continued demand for Augmentin highlights its reliability and strong consumer base in the Indian healthcare system.

USV’s Glycomet GP

Glycomet GP, a leading treatment for diabetes, secures the second position with Rs 796 crore in sales. The brand saw a 4.8% increase in value year-on-year and a 3.0% rise in sales volume for October. Glycomet GP’s success reflects the growing demand for effective diabetes management solutions in India, a country that has seen an alarming rise in diabetes cases.

Abbott’s Mixtard

Abbott’s Mixtard, a popular insulin product, continues to perform strongly in the third position with Rs 747 crore in sales. The brand experienced a 3.8% growth in value and an impressive 12.5% increase in sales volume for October, reflecting the continued rise of diabetes prevalence in India and the increasing need for insulin products.

Alkem’s Pan

Alkem’s Pan has seen a remarkable rise in the rankings, moving to fourth place with Rs 726 crore in sales. The brand experienced a 10.8% value growth over the past year, and a 15.4% increase in sales volume for October. The surge in sales demonstrates Pan’s growing market share in gastrointestinal treatments, making it a key player in the therapeutic area.

Cipla’s Foracort

Foracort, Cipla’s flagship product for respiratory treatments, maintains its position in the fifth spot with Rs 724 crore in sales. The brand has seen a 6.9% increase in value over the past year, and a 7.9% rise in sales volume for October. The growing demand for respiratory medications, particularly for asthma, continues to drive Foracort’s success.

The rankings of several brands saw significant shifts in October 2024. Alkem’s Pan, driven by both value and volume growth, surged from fourth to second position. Similarly, Abbott’s Ryzodeg saw a remarkable 35.3% increase in value, along with a 24.7% rise in sales volume for the month of October. The brand’s strong performance reflects the increased demand for advanced insulin formulations in diabetes management.

FDC’s Electral also saw impressive growth, with a 29.9% increase in sales value for the year, along with a 33.0% rise in sales volume for October. The surge can be attributed to the growing demand for oral rehydration solutions, particularly in regions affected by seasonal illnesses and dehydration.

Despite the positive growth in value across several top-selling brands, volume growth remains a challenge for some. Himalaya’s Liv.52 and Aristo’s Monocef, for instance, faced declines in sales volume, with decreases of -1.0% and -13.4%, respectively. However, both brands managed to retain strong positions in the rankings due to continued value growth.

Also Read: Indian Pharma Market grows at 6.8 percent in October, Chronic Therapies Dominate: IQVIA